Bone Biologics raises $3.0M, with up to $6.0M more tied to warrants
What's the deal? Bone BiologicsDealroom has a profile for this one. Try Dealroom → has raised $3.0 million upfront through a private placement priced at-the-market under Nasdaq rules. The deal could bring in up to roughly $6.0 million in additional gross proceeds if warrants are exercised in full for cash, taking the total to as much as $9.0 million.
How it's structured: The upfront $3.0 million is fixed. The remaining amount is contingent — it depends on investors choosing to exercise their warrants.
Why the pricing matters: Pricing at-the-market under Nasdaq rules means the placement was set in line with the stock's market price. That structure lets Bone Biologics avoid the shareholder-approval requirements that can apply to below-market deals.
The signal: The staged structure — a modest raise now, with a larger potential top-up later — reflects how smaller listed companies are increasingly leaning on warrant-linked private placements to secure near-term cash while leaving room for more.
Read more: Aktiencheck
Image credit: Generated with Gemini
